London-based hedge fund Cheyne Capital is planning a new vehicle to buy up debt that’s been excessively punished by the coronavirus selloff, the latest in a number of investment...
Keep Reading →
May 12 - Hedge Funds, Insider Trading - Comments
Michael Dell’s money managers are making the most significant change in years to how they invest the billionaire’s wealth. MSD Capital, Mr.
Keep Reading →
December 6 - Hedge Funds, Insider Trading - Comments
Sound Shore posted 20 year annualized returns of 7.30% and 7.51% for its Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX), respectively, in its Q1 2019 ...
Keep Reading →
May 13 - Hedge Funds, News - Comments
General Dynamics Corp., the maker of Abrams tanks and nuclear submarines, is making a record bet on reinvigorating its information-technology business. The U.S.
Keep Reading →
February 12 - Market Movers, News - Comments
"U.S. equities traded higher on Wednesday as investors cheered the Federal Reserve's plan for scaling back its massive $4.5 trillion balance sheet.
Keep Reading →
May 24 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech - Comments
"The S&P 500 traded higher on Tuesday and nearly erased the losses suffered from the biggest sell-off of the year.
Keep Reading →
May 23 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has had another misfortune in the UK.
Keep Reading →
February 17 - News, Stock Analysis - Comments
Bringing something new to the table is something that seems to be difficult these days, considering that many things have already been done, have already been invented, and have...
Keep Reading →
October 26 - Hedge Funds, Lists, News - Comments
Crude futures are in the red today as sentiment around the commodity cools off.
Keep Reading →
July 28 - Market Movers, News - Comments
U.S stocks have edged higher on Tuesday following a rise in oil prices and Fed Chairwoman Janet Yellen’s speech on Monday, in which she maintained an optimistic tone about the...
Keep Reading →
June 7 - Market Movers, News - Comments
While several hedge funds have suffered enormous losses this year due to their investments in biotech stocks, the performance of the leading biotech-focused hedge fund Baker Bros...
Keep Reading →
May 7 - Hedge Fund Analysis, Hedge Funds, News - Comments
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker.
Keep Reading →
February 25 - Hedge Funds, News - Comments
Professional money managers are quick to judge when things start to turn sour for a particular company.
Keep Reading →
December 11 - Hedge Funds, News - Comments
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today.
Keep Reading →
December 9 - Hedge Fund Analysis, Hedge Funds, News - Comments
Mariner Investment Group is a New York-based investment advisory firm founded by William Michaelcheck in 1992.
Keep Reading →
November 13 - Hedge Fund Analysis, Hedge Funds, News - Comments
At Insider Monkey, we track over 700 hedge funds and investment companies, which allows us to understand the market sentiment towards any given stock. Baker Bros.
Keep Reading →
August 17 - Hedge Fund Analysis, Hedge Funds, News - Comments
With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker's Baker Bros. Advisors is making a habit of hitting home runs in 2015.
Keep Reading →
July 10 - Hedge Funds, News - Comments
Alexion Pharmaceuticals, Inc.
Keep Reading →
June 30 - Hedge Funds, News - Comments
Orphan drugs, those treating rare conditions for small segments of the population, do not normally get much attention compared with the likes of a $12.9 billion Lipitor -- but...
Keep Reading →
October 11 - Hedge Funds, News - Comments
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur.
Keep Reading →
September 16 - News - Comments
NPS Pharmaceuticals, Inc.
Keep Reading →
September 11 - News - Comments
A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has banked more than a billion...
Keep Reading →
September 9 - News - Comments
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
Keep Reading →
August 29 - News - Comments
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track the equity markets.
Keep Reading →
August 26 - News - Comments
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Keep Reading →
August 26 - News - Comments
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News - Comments
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News - Comments
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News - Comments
At some point, a company reaches a level of maximum valuation. It doesn't mean the company becomes bad, but rather all upside is priced in and future gains are limited.
Keep Reading →
August 22 - News - Comments
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Keep Reading →
August 19 - News - Comments
When a company is acquired, the acquirer pays a large premium to where the acquired company’s stock price had previously been trading.
Keep Reading →
August 13 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July.
Keep Reading →
August 6 - News - Comments
In 2013, a number of new drugs got approvals from the FDA. This provided a boost to the biotech industry as a whole.
Keep Reading →
August 5 - News - Comments
In the last couple of months, we saw two big offers being made - and rejected - in the biotech sector.
Keep Reading →
August 5 - News - Comments
With the SPDR S&P Biotech Index up 43% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 5 - News - Comments
There are few times when your doctor or physician will utter the phrase, "I don't know" to a patient, but when you're dealing with the rarest of diseases, then all bets are off...
Keep Reading →
August 5 - News - Comments
Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors.
Keep Reading →
July 29 - News - Comments
The biotech industry is known for fast paced acquisitions and rapid market consolidation.
Keep Reading →
July 29 - News - Comments
You may or may not have heard, but it's earnings season again.
Keep Reading →
July 22 - News - Comments
In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations. Yet one company ...
Keep Reading →
July 19 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
July 18 - News - Comments
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
Keep Reading →
July 17 - News - Comments
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has a particularly fascinating history, having been at the center of controversy for the better part of its existence. For several ...
Keep Reading →
July 17 - News - Comments
Celldex Therapeutics, Inc. (NASDAQ:CLDX), the first antibody-based immunotherapy company, has been a strong buy recommended by several analysts for some time now.
Keep Reading →
July 17 - News - Comments
According to a Bloomberg report, Roche is prepared to offer $130 a share to purchase Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Keep Reading →
July 15 - News - Comments
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Keep Reading →
July 15 - News - Comments
With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 15 - News - Comments
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don't have to imagine it.
Keep Reading →
July 5 - News - Comments
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Keep Reading →
July 5 - News - Comments
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016.
Keep Reading →
July 3 - News - Comments
